Genetics and Genome Sequencing of Childhood-Onset Neuropsychiatric Disorders. by Lyon,  Gholson J.
Gene$cs	  and	  Genome	  Sequencing	  of	  Childhood-­‐Onset	  
Neuropsychiatric	  Disorders	  
Gholson	  Lyon,	  M.D.	  Ph.D.	  
@GholsonLyon	  
The	  Big	  Picture	  
•  Over	  the	  course	  of	  my	  en<re	  career,	  I	  want	  to	  
help	  understand	  the	  pathophysiology	  of	  severe	  
mental	  disorders,	  including	  such	  things	  as	  
developmental	  delay,	  mental	  retarda<on,	  au<sm,	  
psycho<c	  disorders	  (schizophrenia,	  bipolar,	  
schizoaﬀec<ve),	  ToureGe	  Syndrome	  and	  
obsessive	  compulsive	  disorder.	  
•  I	  expect	  this	  to	  uncover	  new	  biology	  along	  the	  
way.	  
Most	  recent	  analysis	  in	  Europe	  showed	  that	  brain	  disorders	  cost	  almost	  US
$1	  trillion	  year	  per	  year,	  more	  than	  cancer,	  cardiovascular	  disease	  and	  
diabetes	  combined.	  
	  
These	  brain	  disorders	  include:	  
Mood	  disorders	  
Psycho$c	  Disorders	  
Addic<on	  
Anxiety	  
Demen<a	  
Headache	  
Other-­‐	  brain	  tumor,	  child/adolescent	  developmental	  disorders	  (au$sm,	  
ADHD,	  $cs,	  etc…),	  ea<ng	  disorders,	  epilepsy,	  mental	  retarda$on,	  mul<ple	  
sclerosis,	  neuromuscular	  disorders,	  Parkinson’s,	  personality	  disorders,	  sleep	  
disorders,	  somatoform	  disorder,	  stroke	  and	  trauma<c	  brain	  injury.	  
	  
*	  Cost	  of	  disorders	  of	  the	  brain	  in	  Europe	  2010.	  
Gustavsson	  A,	  et	  al.	  
Eur	  Neuropsychopharmacol.	  2011	  Oct;21(10):718-­‐779.	  Epub	  2011	  Sep	  15.	  
	  
	  
The	  toll	  with	  Brain	  Disorders	  is	  tremendous.	  
I	  moved	  to	  Utah	  in	  July	  2009	  to	  ﬁnd	  new	  
human	  gene$c	  syndromes,	  thus	  revealing	  new	  
biology.	  
	  
  July	  2009-­‐December	  2009:	  AUended	  weekly	  
gene$cs	  case	  conference	  in	  which	  10-­‐30	  gene$c	  
cases	  are	  presented	  weekly,	  led	  by	  Dr.	  Alan	  Rope	  
and	  aUended	  by	  Drs.	  John	  Carey	  and	  John	  Opitz.	  
	  
  There	  are	  indeed	  MANY	  idiopathic	  disorders	  not	  
described	  in	  the	  literature,	  many	  of	  which	  have	  
neuropsychiatric	  manifesta$ons.	  I	  thought	  about	  
hundreds	  of	  such	  cases,	  looking	  for	  the	  ideal	  ﬁrst	  
family	  to	  sequence.	  
Discovering	  a	  new	  syndrome	  and	  its	  
gene<c	  basis.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas<c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	  
III 
III 
1 2
1
1
2
2 3 4
3
5 6
4 5 6 7 8
SB 
This	  is	  the	  family	  in	  Utah	  in	  December	  2009.	  
I	  met	  the	  en<re	  family	  on	  March	  29,	  2010	  
Photo	  of	  mother	  
with	  son	  in	  late	  1970’s	  
First	  boy.	  Called	  “a	  liGle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
Uncle	  #1	   Uncle	  #2	   cousin	   Proband-­‐	  SuGer	  
These	  are	  the	  Aﬀected	  Boys	  of	  Family	  1	  in	  2009.	  	  
Aﬀected	  males	  had	  the	  consistent	  presenta<on	  of	  an	  aged	  appearance,	  a	  dis<nct	  
and	  recognizable	  combina<on	  of	  craniofacial	  anomalies,	  post-­‐natal	  growth	  failure,	  
hypotonia,	  global	  developmental	  delays,	  cryptorchidism,	  arrhythmia,	  and	  
eventual	  death	  from	  cardiac	  failure.	  	  
	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
III 
III 
1 2
1
1
2
2 3 4
3
5 6
4 5 6 7 8
SB 
Experimental Design for Sequencing is Critical. 
  We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
  We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota$on,	  Analysis	  and	  
Search	  Tool).	  New	  computa$onal	  tools	  for	  
iden$fying	  disease-­‐causing	  muta$ons	  by	  
individual	  genome	  sequencing.	  	  
	  
Yandell,	  M.	  et	  al.	  2011.	  “A	  probabilis<c	  disease-­‐gene	  ﬁnder	  for	  personal	  
genomes.”	  Genome	  Res.	  21	  (2011).	  doi:10.1101/gr.123158.111.	  	  	  
	  
Wang,	  K.,	  Li,	  M.,	  and	  Hakonarson,	  H.	  (2010).	  ANNOVAR:	  func<onal	  annota<on	  
of	  gene<c	  variants	  from	  high-­‐throughput	  sequencing	  data.	  Nucleic	  Acids	  Res	  
38,	  e164.	  
	  	  
	  
	  
The	  Exon	  Capture	  and	  Coverage	  was	  
high	  depth.	  
!
Table 2. Coverage Statistics in Family 1. Based on GNUMAP 
Region RefSeq Transcripts 
 
Unique 
Exons 
 
Percent 
Exon 
Coverage 
≥1X 
Percent Exon 
Coverage 
≥10X 
Unique 
Genes 
Average Base 
Coverage 
 
VAAST 
Candidate 
SNVs 
 X-chromosome 1,959 7,486  97.8 95.6 913 214.6 
1 
(NAA10) 
chrX: 
10054434- 
40666673 262 1,259  98.1 95.9 134 213.5 
 
 
0 
chrX: 
138927365- 
153331900 263 860  97.1 94.9 132 177.1 
 
1 
(NAA10) 
* On chromosome X, there are 8,222 unique RefSeq exons. Of these exons, 736 were excluded from the SureSelect X-Chromosome Capture 
Kit because they were designated as pseudoautosomal or repetitive sequences (UCSC genome browser). 
Family	  now,	  with	  ﬁve	  muta$on-­‐posi$ve	  boys	  dying	  
from	  the	  disease.	  
I
II 
III 
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6 mt/ 
Ancestry	  MaUers!	  -­‐	  Ogden	  Syndrome	  	  
The	  muta<on	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  suﬃcient	  to	  cause	  this	  
phenotype	  in	  ANY	  gene<c	  background.	  It	  simply	  “contributes	  to”	  the	  phenotype.	  
The	  muta$on	  disrupts	  the	  N-­‐terminal	  
acetyla$on	  machinery	  (NatA)	  in	  
human	  cells.	  	  
Slide	  courtesy	  of	  Thomas	  Arnesen	  
NAT	  ac$vity	  of	  recombinant	  hNaa10p	  
WT	  or	  p.Ser37Pro	  towards	  synthe$c	  
N-­‐terminal	  pep$des	  	  
	  hNaa10p-­‐S37P	  is	  func$onally	  
impaired	  in	  vivo	  using	  a	  yeast	  model.	  
	  
Unpublished	  data	  from	  Thomas	  Arnesen,	  do	  not	  further	  distribute.	  
 Simulated	  structure	  of	  S37P	  mutant	  	  
?	  
Big	  Ques<on:	  
Max	  Doerfel	   Yiyang	  Wu	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
New	  Syndrome	  with	  Dysmorphology,	  Mental	  	  
Retarda<on,	  “Au<sm”,	  “ADHD”	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	   	   	   	  7	  years	  old 	   	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old 	   	   	   	  	  	  9	  years	  old 	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene<c	  tests	  nega<ve,	  including	  nega<ve	  for	  
Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  and	  Two	  
Boys,	  using	  Complete	  Genomics,	  obtained	  data	  in	  June	  
of	  this	  year,	  i.e.	  version	  2.0	  CG	  pipeline.	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  
probe	  anchor	  liga<on	  (cPAL)	  
22,174	  
272	  
56	  
7	  
6	  
5	  
3	  
SIFT	  classiﬁca<on	  
Variant	  classiﬁca<on	  
VAAST	  score	  
Chromosome	   Posi<on	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   Classiﬁca<on	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	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1341
Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
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! 2003 by The American Society of Human Genetics. All rights reserved.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
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A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Sanger	  valida$on:	  	  ASB12	  and	  ZNF41	  muta$ons	  
The	  muta<on	  in	  ZNF41	  may	  NOT	  be	  necessary,	  and	  it	  is	  certainly	  
NOT	  suﬃcient	  to	  cause	  the	  phenotype.	  
So,	  of	  course	  we	  need	  baseline	  whole	  
genome	  sequencing	  on	  everyone	  to	  at	  
least	  understand	  the	  DNA	  gene<c	  
background	  in	  each	  pedigree	  or	  clan.	  
	  
Ancestry	  MaGers!	  

~750	  DNA	  samples	  from	  many	  pedigrees	  with	  455	  of	  
these	  genotyped	  thus	  far	  on	  Illumina	  610K/2.5M	  
arrays	  and	  15	  with	  high-­‐depth	  exome,	  and	  8	  with	  CG	  
whole	  genomes.	  	  
Some	  Deﬁni<ons	  …	  
•  The	  words	  “penetrance”	  and	  “expressivity”,	  deﬁned	  
classically	  as:	  
•  Penetrance:	  whether	  someone	  has	  ANY	  symptoms	  of	  a	  
disease,	  i.e.	  all	  or	  none,	  0%	  or	  100%.	  Nothing	  in	  between.	  
•  Expressivity:	  how	  much	  disease	  (or	  how	  many	  symptoms)	  
someone	  with	  100%	  penetrance	  has.	  
•  This	  has	  led	  to	  endless	  confusion!	  	  
•  Some	  just	  use	  the	  word	  “penetrance”	  to	  mean	  the	  
expressivity	  of	  disease,	  i.e.	  incomplete	  penetrance,	  and	  
maybe	  we	  should	  combine	  the	  two	  terms	  into	  ONE	  word	  
with	  the	  full	  expression	  from	  0-­‐100%	  of	  phenotypic	  
spectrum.	  
Genotype	  First,	  Phenotype	  Second	  
AND	  Longitudinally	  
Phenotypic variability and genetic susceptibility
to genomic disorders
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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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Objective: The authors used a genome-
wide association study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 individuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia- ss ciated rare CNVs.
Results: No genome-wide signiﬁcant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had signiﬁcantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previou case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and ses in l rge case-control st dies. Our
ﬁndings are consistentwith a role for speciﬁc
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studied.
Am J Psychiatry Levinson et al.; AiA:1–11
We report here on the ﬁrst genome-wide associ-
ation study (GWAS) in families with multiple members
with schizophrenia. Signiﬁcant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanisms. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histocompatibility complex
(MHC, chromosome 6) (1–3) and several speciﬁc genes
AJP in Advanced ajp.psychiatryonline.org 1
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“Rare	  CNVs	  wer 	   bserve 	  in	  regions	  with	   trong	  previ u ly	   cum n ed	  associa<on	  
with	  schizophrenia,	  but	  with	  variable	  paGerns	  of	  segrega<on.	  This	  should	  serve	  as	  a	  
reminder	  that	  we	  s<ll	  know	  rela<vely	  liGle	  about	  the	  distribu<on	  of	  these	  CNVs	  in	  the	  
en<re	  popula<on	  (e.g.,	  in	  individuals	  with	  no	  or	  only	  mild	  cog i<ve	  problems)	  or	  about	  
the	  reas ns	   or	  the	  emerg nce	   f	  sc izophrenia	  in	  only	  a	   inority	   f	  c rriers,	  so	  great	  
cau<on	  is	  required	  in	  gene<c	  counseling	  and	  prediagnosis.”	  	  
	  
Deﬁni$ons.	  It	  is	  unknown	  what	  
por<on	  of	  au<sm	  will	  be	  oligogenic	  vs.	  
polygenic	  
•  Oligogenic	  –	  mul<ple	  muta<ons	  together	  
contribu<ng	  to	  aggregate	  disease,	  BUT	  with	  only	  
1	  muta<on	  of	  ~	  >10%	  penetrance	  (or	  “eﬀect	  size)	  
in	  EACH	  person.	  
•  Polygenic	  –	  Dozens	  to	  hundreds	  of	  muta<ons	  in	  
diﬀerent	  genes	  in	  the	  SAME	  person,	  together	  
contribu<ng	  to	  the	  disease	  in	  the	  SAME	  person,	  
hence	  addi$ve	  and/or	  epista$c	  contribu<on	  with	  
~0.01-­‐1%	  penetrance	  for	  each	  muta<on.	  
Example	  of	  Polygenic	  Model	  
Visscher	  et	  al.	  2011	  

Inheritance	  PaUern	  of	  Copy-­‐Number	  Variants	  and	  Frequency	  of	  Second-­‐Site	  Variants	  Associated	  with	  a	  Genomic	  
Disorder.	  
Girirajan S et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200395 
Waddington	  claimed	  that	  canals	  form	  in	  the	  epigene$c	  
landscape	  during	  evolu$on,	  and	  that	  this	  heuris$c	  is	  useful	  for	  
understanding	  the	  unique	  quali$es	  of	  biological	  robustness.	  
The	  canalisa<on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba<ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  liGle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba<ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  liGle	  robustness	  beyond,	  is	  a	  paGern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua<ng	  environment.	  
“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta<onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta<onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta<ons	  
were	  compa<ble	  with	  gradual	  evolu<on:	  see	  the	  
modern	  evolu<onary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques<ons	  our	  scien<ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene<cs	  and	  Thomas	  Kuhn's	  legacy	  
hGp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi<on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
E.	  coli	  adap<ng	  to	  low	  glucose	  condi<ons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
"Finally,	  novel	  func<ons	  oen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuni<es.	  This	  three-­‐step	  process	  —	  in	  which	  poten<a<on	  
makes	  a	  trait	  possible,	  actualiza<on	  makes	  the	  trait	  manifest,	  and	  reﬁnement	  makes	  
it	  eﬀec<ve	  —	  is	  probably	  typical	  of	  many	  new	  func<ons.”	  -­‐	  Lemski	  
Genomic	  analysis	  of	  a	  key	  innova<on	  in	  an	  experimental	  Escherichia	  coli	  popula<on.	  
Blount	  ZD,	  Barrick	  JE,	  Davidson	  CJ,	  Lenski	  RE.	  
Nature.	  2012	  Sep	  19.	  doi:	  10.1038/nature11514	  
	  
Ancestry	  MaUers!	  -­‐	  Ogden	  Syndrome	  	  
The	  muta<on	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  suﬃcient	  to	  cause	  this	  
phenotype	  in	  ANY	  gene<c	  background.	  It	  simply	  “contributes	  to”	  the	  phenotype.	  
Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  
expressivity	  of	  	  preGy	  much	  ALL	  muta<ons	  in	  
humans,	  as	  we	  have	  not	  systema<cally	  
sequenced	  or	  karyotyped	  any	  gene<c	  altera<on	  
in	  MILLIONS	  of	  well-­‐phenotyped	  people.	  
•  Do	  single	  muta<ons	  drive	  outcome	  
predominately,	  or	  are	  the	  results	  modiﬁed	  
substan<ally	  by	  other	  muta<ons	  and/or	  
environment?	  	  Is	  there	  really	  such	  a	  thing	  as	  
gene<c	  determinism	  for	  MANY	  muta<ons?	  


OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
695
NOTES AND COMMENTS 697
The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
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“Those	  who	  hav 	  given	  any	  aG n< n	  to	  congenital	  mental	  
lesions,	  must	  have	  been	  frequently	  puzzled	  how	  to	  arrange,	  in	  
any	  sa<sfactory	  way,	  the	  diﬀerent	  classes	  of	  this	  defect	  which	  
may	   ave	  come	  under	  their	  observa<on.	  Nor	  will	  the	  diﬃculty	  be	  
lessened	  by	  an	  appeal	  to	  what	  has	  been	  wriGen	  on	  the	  subject.	  
The	  systems	  of	  classiﬁca<on	  are	  generally	  so	  vague	  and	  ar<ﬁcial,	  
that,	  not	  only	  do	  they	  assist	  but	  feebly,	  in	  any	  mental	  
arra gement	  of	  the	  phenomena	  represented,	  but	  they	  
completely	  fail	  in	  exer<ng	  a y	  prac<cal	  inﬂuenc 	  on	  the	  subject.”	  
	  
	  
Published	  in	  “Biology	  of	  Mental	  Defect”,	  by	  Lionel	  Penrose,	  1949	  
And	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  



Down	  Syndrome	  

Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2 deletion 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (a and b) Proband 2 (de novo deletion 16p11.2). Note long 
narrow palpebral fissures, short delicate nose, short neck and brachydactyly with 
2–3 cutaneous toe syndactyly. (c and d) Mother of proband 3 (both with 
deletions). Note her large ears, smooth philtrum and short fifth toes. 	  
16p11.2 duplication 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (e) Proband 5 who has a maternally inherited 
duplication. (f) Proband 5 (note smooth philtrum) and her healthy duplication 
positive sister. (g) Duplication positive mother of proband 5, who also has a 
smooth philtrum. (h) Proband 6 (inherited duplication and oliogohydramnios 
sequence). Note her frontal bossing, receding hairline, hypoplastic 
supraorbital ridges and smooth philtrum. (i) Proband 6's right hand showing 
fifth finger clinodactyly. 	  
16p11.2	  dele<on,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  developmental	  
age	  of	  2	  year	  old.	  
Speaks	  a	  few	  words,	  almost	  
unintelligible.	  
Very	  hyperac<ve.	  
Can	  be	  withdrawn	  and	  has	  at	  
<mes	  been	  diagnosed	  with	  
“au<sm”.	  
*Private	  Photograph	  –	  Do	  not	  further	  distribute.	  

Clinical	  Management	  and	  Gene<cs	  
Genet	  Med.	  2011	  Sep;13(9):770-­‐6.	  
	  
Chromosomal	  microarray	  tes$ng	  inﬂuences	  medical	  management.	  
Coulter	  ME,	  Miller	  DT,	  Harris	  DJ,	  Hawley	  P,	  Picker	  J,	  Roberts	  AE,	  Sobeih	  MM,	  Irons	  M.	  
	  
PURPOSE:	  	  
Chromosomal	  microarray	  (CMA)	  tes<ng	  provides	  the	  highest	  diagnos<c	  yield	  for	  clinical	  tes<ng	  of	  
pa<ents	  with	  developmental	  delay	  (DD),	  intellectual	  disability	  (ID),	  mul<ple	  congenital	  anomalies	  
(MCA),	  and	  au<sm	  spectrum	  disorders	  (ASD).	  Despite	  improved	  diagnos<c	  yield	  and	  studies	  to	  support	  
cost-­‐eﬀec<veness,	  concerns	  regarding	  the	  cost	  and	  reimbursement	  for	  CMA	  have	  been	  raised	  because	  
it	  is	  perceived	  that	  CMA	  results	  do	  not	  inﬂuence	  medical	  management.	  
METHODS:	  	  
We	  conducted	  a	  retrospec<ve	  chart	  review	  of	  CMA	  tes<ng	  performed	  during	  a	  12-­‐month	  period	  on	  
pa<ents	  with	  DD/ID,	  ASD,	  and	  congenital	  anomalies	  to	  determine	  the	  propor<on	  of	  cases	  where	  
abnormal	  CMA	  results	  impacted	  recommenda<ons	  for	  clinical	  ac<on.	  
RESULTS:	  	  
Among	  1792	  pa<ents,	  13.1%	  had	  clinically	  relevant	  results,	  either	  abnormal	  (n	  =	  131;	  7.3%)	  or	  variants	  
of	  possible	  signiﬁcance	  (VPS;	  n	  =	  104;	  5.8%).	  Abnormal	  variants	  generated	  a	  higher	  rate	  of	  
recommenda<on	  for	  clinical	  ac<on	  (54%)	  compared	  with	  VPS	  (34%;	  Fisher	  exact	  test,	  P	  =	  0.01).	  CMA	  
results	  inﬂuenced	  medical	  care	  by	  precipita<ng	  medical	  referrals,	  diagnos<c	  imaging,	  or	  speciﬁc	  
laboratory	  tes<ng.	  
CONCLUSIONS:	  	  
For	  all	  test	  indica<ons,	  CMA	  results	  inﬂuenced	  medical	  management	  in	  a	  majority	  of	  pa<ents	  with	  
abnormal	  variants	  and	  a	  substan<al	  propor<on	  of	  those	  with	  VPS.	  These	  results	  support	  the	  use	  of	  
CMA	  as	  a	  clinical	  diagnos<c	  test	  that	  inﬂuences	  medical	  management	  for	  this	  pa<ent	  popula<on.	  
Laurence-­‐Moon	  Syndrome,	  now	  known	  as	  Bardet-­‐Biedl	  Syndrome	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Master	  Crasman	  
Most	  famously	  designed	  The	  Great	  
Eastern,	  a	  10	  foot	  long	  model	  ship	  
with	  incredible	  detail.	  
	  
Deaf	  and	  nearly	  mute	  –	  Nonverbal,	  
Obsessed	  with	  one	  topic	  of	  
building	  things.	  
Thought	  to	  be	  mentally	  retarded.	  
Usually	  quiet	  and	  reserved,	  but	  
some<mes	  was	  intolerant	  of	  
advice,	  suspicious	  of	  strangers,	  and	  
ill-­‐tempered	  and	  violent.	  
“The	  clinical	  and	  pathological	  
evidence	  of	  a	  pervasive	  
developmental	  disorder	  points	  to	  a	  
retrospec<ve	  diagnosis	  of	  au<sm.”	  
Historical 
The Victorian genius of Earlswood - a 
review of the case of James Henry Pullen 
Caoimhghin S Breathnach, Conor Ward 
Summary 
London born James Henry Pullen (1836-1915) was 
admitted to Essex Hall in Colchester, an institution catering 
for learning disability, at the age of 13. Here his artistic 
talent was spotted before he moved two years later to 
Earlswood Asylum for Idiots, where he was apprenticed to 
woodworking. Such was his manual skill he was eventually 
employed making furniture for the asylum. His artistic 
propensity was similarly encouraged and although he never 
mastered coherent speech he has left a pictorial 
autobiography of some distinction. At observation he 
underwent detailed examination by Frederich Sano (1871-
1946), particular attention being paid to tokens of arrested 
development. The clinical and pathological evidence of a 
pervasive developmental disorder points to a retrospective 
diagnosis of autism. 
Key words: History; Autism; Victorian genius; Learning 
disability; Developmental disorder. 
Introduction 
In 1870 Sequin described children who had 'a useless 
protrusion of a single faculty accompanied by a woeful 
general impotence'.' Langdon Down introduced the term 
idiots savants to describe them.' The first idiot savant recog-
nised in England was Jedediah Buxton, an illiterate 
Derbyshire farmhand who could multiply two 39 digit 
numbers.3 Of the seven cases described by Langdon Down, 
the best known was James Henry Pullen, known colloquially 
as the Genius of Earlswood. Langdon Down's identification 
of the syndrome had previously been referred to in 1865.' 
Clinical history 
Pullen's parents were first cousins. They lived in Peckham 
in south London. Of 13 children six died in infancy and only 
three survived into adult life.' His brother William too, also 
cared for in an institution, had exceptional artistic skills. James 
Henry combined primitive speech with sign language. He 
could not write in coherent sentences, but he drew over 80 
sketches illustrating his life. These present a unique life story. 
Boats fascinated him from an early age. Wearing skirts, and 
not yet in breeches, he is seen at the age of nine years 
making a crude model ship from a wooden box. (Figure 1, left 
*Caoimhghin 5 Breathnach, MD, PhD, 
Con or Ward, MD, PhD, FRCPl, Departments of Anatomy & 
Physiology, Paediatrics and Maurice Kennedy Research Centre 
for Emeritus Staff, NUl University College Dublin, Ireland. 
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pane1. Boys usually graduated to wearing breeches at the 
age of six years. Assuming that he inscribed the correct date 
his being still unbreeched at this late age suggests that he 
was seen in the family to have failed to reach an appropriate 
developmental age. The next year he watches an adult, 
maybe his father, sailing a crude three-masted sailing ship -
possibly his improved design- in a pond (Figure 1, middle 
pane1. When he was 12 he visited London. To him it was not 
a city of roads and shops and carriages but a great waterway 
alive with sailing activity (Figure 1, right pane1. In 1901 his 
sister, Mrs Earwicker, set out her memory of his early life. His 
first word was 'muvver'. No school would take him because 
he seemed to be unable to learn. He spent his time at home 
making ships from firewood, cotton and pins. In 1848, aged 
13, he was admitted to Essex Hall in Colchester, an institu-
tion catering for learning disability.' 
Essex Hall which later became the Royal Eastern Counties 
Asylum, was a charity set up by Rev Andrew Reed. It was 
here that his artistic talent was uncovered. In his pictorial 
autobiography he shows himself in 1848 drawing at a school 
table. There is no other young person in the picture, suggest-
ing that he was being taught on his own outside school hours 
(Figure 2, left pane1. The time on the clock is 1.45, school 
finished at 1.00. On this assumption the benign female pres-
ence is likely to be that of Mrs Sarah Pearce, identified in the 
Census of 1851 as the 38-year-old schoolmistress. Was it 
she who opened up new artistic horizons for him? The follow-
ing year, by which time he had learned to write his surname, 
he went on the Essex Hall outing to Walton-on-the-Naze. He 
portrayed a man leading the way towards the harbour. The 
masts of a ship stand out over the promenade wall. Mrs 
Pearce's husband Henry, a porter aged 40, may have been 
his guide. 
In 1850 James was moved to the Earlswood Asylum for 
Idiots, another institution set up by Andrew Reed. The Essex 
Hall educational programme had been very progressive,' and 
the young man portrays himself looking sadly back at Essex 
Hall and at his collection of 1 2 pictures, three of them depict-
ing boats (Figure 2, middle pane1. The configuration of the 
window does not match the shape of the windows in a 
contemporary sketch of Essex hall, suggesting that his work 
had been put on display in another location. 
He was put into the school at Earlswood, but his self-
portrait of 1851 is of a boy with his head buried in the tearful 
despair of failure (Figure 2, right pane1. By 1852, however, 
he was apprenticed to woodwork and boatmaking, and at his 
second attempt he produced a three-masted ship which he 
thought good enough to present to his teacher as a mark of 
appreciation (Figure 3, left pane1. His apprenticeship to 
woodworking led to the progressive complexity of his model-
ling especially after 1859. John Langdon Down, the newly 
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Sibling	  Defense	  Theory	  
•  Defense	  or	  modiﬁer	  Genes?	  –	  muta<ons	  that	  
somehow	  protect	  against	  or	  modify	  the	  eﬀects	  
of	  a	  primary	  muta<on.	  
•  Or,	  can	  female	  gender	  also	  somehow	  be	  
protec<ve	  with	  certain	  muta<ons?	  
•  Henry	  Pullen	  was	  one	  of	  13	  children,	  but	  only	  
3	  lived	  to	  adult	  life.	  His	  brother,	  William,	  was	  
also	  ins<tu<onalized	  and	  had	  excep<onal	  
ar<s<c	  skills.	  Their	  parents	  were	  ﬁrst	  cousins.	  
=ASD	  
=Odd,	  poten<al	  
broader	  
phenotype	  
=ADHD	  =ASD	  
=Odd,	  poten<al	  
broader	  
phenotype	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa$entsLikeMe	  

For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Implemen<ng	  Standards	  for	  a	  “clinical-­‐grade”	  exome,	  
and	  promo<ng	  the	  “networking	  of	  science”	  model.	  
•  Focusing	  on	  rare,	  highly	  penetrant	  muta<ons	  running	  
in	  families,	  with	  cascade	  carrier	  tes<ng	  of	  even	  more	  
rela<ves	  as	  needed.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some<mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  ﬁgure	  out	  penetrance	  of	  rare	  
variants	  in	  these	  families,	  along	  with	  other	  issues,	  
such	  as	  soma<c	  mosaicism.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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